Skip to main content

letter

. 1994 May;69(5):976–977. doi: 10.1038/bjc.1994.189

Prolonged continuous infusion of low-dose rIL-2.

R A Janssen, J Buter, T H The, N H Mulder, L de Leij

PMCID: PMC1968897 PMID: 8180034

976

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Ioannides C. G., Whiteside T. L. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol. 1993 Feb;66(2):91–106. doi: 10.1006/clin.1993.1012. [DOI] [PubMed] [Google Scholar]
Janssen R. A., Buter J., Straatsma E., Heijn A. A., Sleijfer D. T., de Vries E. G., Mulder N. H., The T. H., de Leij L. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Cancer Immunol Immunother. 1993;36(3):198–204. doi: 10.1007/BF01741092. [DOI] [PMC free article] [PubMed] [Google Scholar]
Maas R. A., Dullens H. F., Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother. 1993;36(3):141–148. doi: 10.1007/BF01741084. [DOI] [PMC free article] [PubMed] [Google Scholar]
Parmiani G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today. 1990 Apr;11(4):113–115. doi: 10.1016/0167-5699(90)90046-c. [DOI] [PubMed] [Google Scholar]
Vlasveld L. T., Hekman A., Vyth-Dreese F. A., Rankin E. M., Scharenberg J. G., Voordouw A. C., Sein J. J., Dellemijn T. A., Rodenhuis S., Melief C. J. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer. 1993 Sep;68(3):559–567. doi: 10.1038/bjc.1993.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
Weil-Hillman G., Schell K., Segal D. M., Hank J. A., Sosman J. A., Sondel P. M. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment. J Immunother (1991) 1991 Aug;10(4):267–277. doi: 10.1097/00002371-199108000-00005. [DOI] [PubMed] [Google Scholar]
Yoshino I., Yano T., Murata M., Ishida T., Sugimachi K., Kimura G., Nomoto K. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2. Cancer Res. 1991 Mar 1;51(5):1494–1498. [PubMed] [Google Scholar]

ACTIONS

RESOURCES